Heart Drug Spotlights Troubling Trends In Drug Marketing
Critics worry the marketing of Vascepa, a purified fish oil product, could prove a fish story.
The independent source for health policy research, polling, and news.
2,221-2,240 of 4,053 results
Critics worry the marketing of Vascepa, a purified fish oil product, could prove a fish story.
The money was paid on behalf of more than 400,000 people who may have been ineligible for the public program, a state audit found. One had been dead for four years before payments stopped.
Medical treatments targeting the DNA in tumor cells are celebrated, but insurers often won’t cover the skyrocketing cost.
Although dialysis provider DaVita Inc. has taken major financial hits this year, including a $383.5 million jury award in response to wrongful death lawsuits, it still rakes in profits. The company faces its biggest threat next month, when California voters weigh in on a ballot initiative that could force it to leave the state.
A California college professor never imagined that trying to figure out what was causing her rash could add up to such a huge bill.
Union-backed initiatives in Palo Alto and Livermore, Calif., aim to cap charges by hospitals and doctors, seeking to build on national furor over rising medical bills. The measures arise in health care markets that are among the most expensive in the nation.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Kimberly Leonard of the Washington Examiner and Alice Ollstein of Politico discuss a flurry of proposals from the Trump administration on prices Medicare pays for drugs and the Affordable Care Act.
Federal law guarantees that people have the right to see and obtain a copy of their medical records. But, hospitals, doctors, pharmacies and insurance companies often erect obstacles.
As rates of sexually transmitted diseases surge, public health officials want physicians to step up screening and treatment of patients.
Candidates are charging toward midterm elections on a platform of single-payer and universal coverage rhetoric. Yet “Medicare-for-all” and single-payer mean different things to different people.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Insurance companies profit from government contracts but are subject to little oversight of how they spend the money or care for patients. The expansion of Medicaid under the Affordable Care Act has only exacerbated the problem.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Rebecca Adams of CQ Roll Call, Stephanie Armour of The Wall Street Journal and Joanne Kenen of Politico discuss how protections for people with preexisting conditions have become a top issue in the elections, Trump administration efforts to make prescription drug prices more public and the start of Medicare’s annual open-enrollment period. Plus, Rovner interviews California Attorney General Xavier Becerra.
In the wake of a KHN/USA Today Network investigation, Leapfrog will check the safety and quality of outpatient centers.
Drugmakers' contributions to lawmakers have peaked as surging drug prices emerge as a hot-button political issue. In the past decade, Congress has received nearly $79 million from 68 pharma PACs, run by employees of companies that make drugs treating everything from cancer to erectile dysfunction.
Drug pricing is a top issue in the run-up to the midterm elections.
The private health plans that are an alternative to government-run Medicare continue to grow despite the Affordable Care Act’s cuts of billions of dollars in funding.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
© 2026 KFF